Antithrombins

• 

  Subject Areas on Research

  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Antithrombin Supplementation in Patients at Risk for Antithrombin Deficiency After Cardiac Surgery. 
  • A Step Toward Balance: Thrombin Generation Improvement via Procoagulant Factor and Antithrombin Supplementation. 
  • A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. 
  • A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation. 
  • A marriage of enhancement: fibrinolysis and conjunctive therapy. 
  • A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation. 
  • Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. 
  • Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. 
  • Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. 
  • Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis From the National Cardiovascular Data Registry. 
  • Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. 
  • Anticoagulant therapy for percutaneous coronary intervention. 
  • Anticoagulant therapy in unstable angina. 
  • Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. 
  • Antiplatelet and antithrombin therapies in the acute coronary syndromes. 
  • Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma. 
  • Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass. 
  • Antithrombin: anti-inflammatory properties and clinical applications. 
  • Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Argatroban and Bivalirudin for Perioperative Anticoagulation in Cardiac Surgery. 
  • Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients. 
  • Bivalirudin in off-pump coronary artery bypass graft in a patient with heparin-induced thrombocytopenia: a case report of its use. 
  • Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. 
  • Bivalirudin: a review of the pharmacology and clinical application. 
  • Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers. 
  • Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? 
  • Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO. 
  • Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). 
  • Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. 
  • Coagulopathy in α-galactosyl transferase knockout pulmonary xenotransplants. 
  • Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. 
  • Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. 
  • Dabigatran abrogates brain endothelial cell permeability in response to thrombin. 
  • Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. 
  • Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. 
  • Dabigatran-related coagulopathy: when can we assume the effect has "worn off"? 
  • Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. 
  • Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). 
  • Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. 
  • Diagnosis and treatment of acute coronary ischemic syndromes: a update for 1995. 
  • Direct Thrombin Inhibition During Left-Sided Catheter Ablation: More Than Just an Alternative? 
  • Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort. 
  • Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. 
  • Direct thrombin inhibitors. 
  • Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. 
  • Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Effects of Antithrombin Versus Placebo on the Coagulation System in Infants with Low Antithrombin Undergoing Congenital Cardiac Surgery. 
  • Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). 
  • Effects of a plasma-derived C1 esterase inhibitor on hemostatic activation, clot formation, and thrombin generation. 
  • Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. 
  • Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors. 
  • Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. 
  • Expert consensus on treatment strategies in non- ST-segment elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention--an evidence-based review of clinical trial results and treatment guidelines from an emergency medicine perspective: report on a roundtable discussion. 
  • Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-κB-dependent pathways. 
  • Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). 
  • Fibrinolysis for acute myocardial infarction: the future is here and now. 
  • Frequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study). 
  • Heparin Resistance - Clinical Perspectives and Management Strategies. 
  • Heparin resistance and antithrombin: should it still be called heparin resistance? 
  • Heparin-Induced Thrombocytopenia: A Focus on Thrombosis. 
  • Heparin-induced decrease in circulating antithrombin-III. 
  • Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. 
  • Idarucizumab for dabigatran overdose. 
  • Impact of Non-Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective. 
  • Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. 
  • Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). 
  • Influence of clinical trial participation on subsequent antithrombin use. 
  • Interference of thrombin in immunological assays for hirudin specific antibodies. 
  • Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. 
  • Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. 
  • Letter by Van de Werf et al regarding article, "using dabigatran in patients with stroke: a practical guide for clinicians". 
  • Local drug delivery of argatroban from a polymeric-metallic composite stent reduces platelet deposition in a swine coronary model. 
  • Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin. 
  • Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE). 
  • Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. 
  • New oral anticoagulant-induced bleeding: clinical presentation and management. 
  • Newly Developed Recombinant Antithrombin Protects the Endothelial Glycocalyx in an Endotoxin-Induced Rat Model of Sepsis. 
  • Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality. 
  • Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation. 
  • Novel intravenous antithrombins. 
  • Novel oral anticoagulants in gastroenterology practice. 
  • Novel pharmacologic approaches to reduce bleeding. 
  • Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. 
  • Pharmacokinetics of recombinant transgenic antithrombin in volunteers. 
  • Positive outcome after intentional overdose of dabigatran. 
  • Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States. 
  • Prediction of Early Death in Patients With Sepsis-Associated Coagulation Disorder Treated With Antithrombin Supplementation. 
  • Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis. 
  • RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. 
  • Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. 
  • Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes. 
  • Recombinant antithrombin: production and role in cardiovascular disorder. 
  • Recombinant hirudin for prevention of experimental postoperative intraocular fibrin. 
  • Recombinant hirudin prevents postoperative fibrin formation after experimental cataract surgery. 
  • Regulation of thrombin activity--pharmacologic and structural aspects. 
  • Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. 
  • Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention. 
  • Role of the gamma-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin. 
  • Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. 
  • Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. 
  • Sepsis-Induced Coagulopathy and Japanese Association for Acute Medicine DIC in Coagulopathic Patients with Decreased Antithrombin and Treated by Antithrombin. 
  • Serial changes of natural antithrombotics during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. 
  • Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. 
  • Sodium binding site of factor Xa: role of sodium in the prothrombinase complex. 
  • The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry CathPCI Registry. 
  • The effects of argatroban on thrombin generation and hemostatic activation in vitro. 
  • The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials. 
  • The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran. 
  • Thrombin and hemin as central factors in the mechanisms of intracerebral hemorrhage-induced secondary brain injury and as potential targets for intervention. 
  • Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. 
  • Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. 
  • Thrombolytic, antithrombin, and antiplatelet treatment of acute coronary syndromes. 
  • Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy. 
  • Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry. 
  • Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. 
  • Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology